NAE Inhibitor; MLN4924

Biochem/physiol Actions

Reversible: no

Primary TargetNEDD8-Activating Enzyme

Cell permeable: yes

General description

A cell-permeable AMP mimetic that targets the NEDD8-activating E1 enzyme NAE nucleotide-binding site and undergoes a NAE-catalyzed covalent NEDD8 adduct formation, the adduct in turn acts as a tight-binding, ATP-competitive NAE inhibitor (IC₅₀ = 4.7 nM), exhibiting much reduced or little potency against Ub-activating enzyme UAE/UBA1, Ub-like modifier activating enzyme UBA6/UBE1L2, SUMO activating enzyme SAE, Ub-like modifier activating enzyme ATG7 (IC₅₀ = 1.5, 1.8, 8.2, and >10 µM, respectively), adenosine receptors A₁/A_2A/A_2B/A₃, or a panel of 12 cellular kinases (IC₅₀ >10 µM). Selectively reduces cellular Ubc12-NEDD8, but not Ubc9-SUMO or Ubc10-Ub, thioester formation (IC_max = 90 nM in HCT-116 cultures in 24 h), resulting in build-up of CRLs (cullin-RING ligases) substrates CDT1, NFE2L2/NRF2, and p27, without affecting overall cellular protein turnover. Shown to inhibit the growth of cancers of various origins both in cultures (IC₅₀ from 50 nM to 1.03 µM) in vitro and in murine xenograft models (30 to 60 mg/kg; q.d. or b.i.d via s.c.) in vivo via apoptosis induction.

A cell-permeable AMP mimetic that targets the NEDD8-activating E1 enzyme NAE nucleotide-binding site and undergoes a NAE-catalyzed covalent NEDD8 adduct formation, the adduct in turn acts as a tight-binding, ATP-competitive NAE inhibitor (IC₅₀ = 4.7 nM), exhibiting much reduced or little potency against UAE/UBA1, UBA6/UBE1L2, SAE, ATG7, adenosine receptors A₁/A_2A/A_2B/A₃, or a panel of 12 cellular kinases. Selectively reduces cellular Ubc12-NEDD8, but not Ubc9-SUMO or Ubc10-Ub, thioester formation (IC_max = 90 nM in HCT-116 cultures in 24 h), resulting in cullin-RING ligases substrates elevation. Shown to inhibit the growth of various cancer cells both in cultures (IC₅₀ from 50 nM to 1.03 µM) in vitro and in murine xenograft models (30 to 60 mg/kg via s.c.) in vivo via apoptosis induction.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Milhollen, M.A., et al. 2010. Blood116, 1515.r>Brownell, J.E., et al. 2010. Mol. Cell37, 102.r>Soucy, T.A., et al. 2009. Nature458, 73.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Use only fresh DMSO for reconstitution.

Warning

Toxicity: Standard Handling (A)